Article | June 22, 2021

Payers Create CAR-T Approval Systems As Adoption Increases

Source: Precision ADVANCE

By Jane Anderson

T cell cancer research iStock-981878366

Content featured by Precision Value & Health

Spurred by CMS’s decision to cover CAR-T cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up. In this article experts weigh in on factors driving authorizations now and what to expect as more CAR-T therapies are approved.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene